ArticleAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry2026
An integrated microfluidic system for automatic and self-validated analysis of cervical extracellular vesicle markers PD-L1 and ERBB3.
Article in Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The early and precise diagnosis of gynecological malignancies, such as cervical cancer, is critical for improving patient treatments. Extracellular vesicles (EVs), such as exosomes, which carry molecular signals from their parental cells, offer a promising method for non-invasive liquid biopsy, however, conventional detection methods are often complex, high in reagent consumption, and susceptible to environmental fluctuations. To address this, we present an integrated, self-validated microfluidic system for the rapid, on-chip isolation and multiplexed identification of the gynecological EV markers PD-L1 and ERBB3. The chip achieved simultaneous on-chip processing of test and positive samples for parallel analysis within 1 h, enabling synchronous detection under the same conditions and thereby significantly enhancing the reliability of the assay. Additionally, a deep learning YOLOv8-based self-validated detection strategy facilitates automated and precise fluorescence identification. Validation with four cell lines (SiHa, C33A, HeLa, and H8) revealed remarkable EV protein signatures, achieving a limit of detection (LOD) of 15.56 particles/μL. This platform provides an integrated tool for sensitive and precise EV marker analysis, holding prospective potential for the early screening and personalized therapy guidance of gynecological tumor detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.